Please ensure Javascript is enabled for purposes of website accessibility

BioNTech Gets Green Light to Start Coronavirus Vaccine Trials in Germany

By Cory Renauer – Apr 22, 2020 at 11:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pfizer's European biotech partner will soon begin early-stage testing of four experimental SARS-CoV-2 vaccines.

German immunotherapy specialist BioNTech SE (BNTX 2.08%), which is collaborating with Pfizer (PFE 0.59%) on a potential coronavirus vaccine, on Wednesday received regulatory permission to begin phase 1/2 clinical trials of its lead candidates in Germany.

It was just over a month ago, on March 17, that Pfizer and BioNTech agreed to join forces to attempt to develop a vaccine for SARS-CoV-2, the coronavirus that causes COVID-19. Now, the Paul-Ehrlich-Institut -- which is both a research institute and one of Germany's medical regulators -- has given them the go-ahead to conduct human studies of the experimental vaccines from their BNT162 program. A similar green light to begin trials in the U.S. is expected shortly.

Pipetting tray close up

Image source: Getty Images.

The BNT162 program is actually a collection of four experimental coronavirus vaccines, all of which use different messenger RNA (mRNA) formats to produce one of two selected target antigens. Two of the candidates employ mRNA strands that function as templates for the production of the big spikes found on the surface of SARS-CoV-2. The other two help patients produce copies of a smaller (but hopefully more recognizable) region of the coronavirus spike protein.

A good deal

On April 9, Pfizer handed BioNTech an upfront payment of $185 million and promised it up to $563 million in potential milestone payments. If the BNT162 program produces a successful vaccine, the partners will split the costs of development and commercialization. If the vaccine never reaches commercialization, though, Pfizer will pay for 100% of the development costs.

In the first part of the planned trial in Germany, investigators will inject around 200 healthy patients with one of the four candidates in doses ranging from 1 microgram to 100 micrograms. But at this early trial stage, the researchers are largely looking to determine the optimal dosage, whether the vaccines are safe, and whether they generate the hoped-for immune system response. The question of whether any of them effectively prevents COVID-19 transmission will have to wait for larger, later-stage trials. And while the partners are moving at top speed on this vaccine project, it could be a long time before that question is answered.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$130.30 (2.08%) $2.65
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.09 (0.59%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.